Metoclopramide intranasal - Evoke Pharma

Drug Profile

Metoclopramide intranasal - Evoke Pharma

Alternative Names: Emitasol; EVK 001; Gimoti™; Pramidin

Latest Information Update: 07 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Questcor Pharmaceuticals
  • Developer Evoke Pharma; Questcor Pharmaceuticals
  • Class Aminobenzoic acids; Antiemetics; Antineoplastics; Benzamides; Chlorobenzenes; Diethylamines; Gastrokinetics; Phenyl ethers; Radiation-sensitising agents; Radiosensitisers; Small molecules
  • Mechanism of Action Dopamine receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting
  • Phase III Diabetic gastroparesis
  • Discontinued Gastroparesis

Most Recent Events

  • 05 Mar 2018 Evoke Pharma intends to launch metoclopramide intranasal for Diabetic gastroparesis (female-only) in USA in 2019
  • 05 Mar 2018 The US FDA Approves PDUFA Fee Waiver for metoclopramide intranasal New Drug Application for Diabetic gastroparesis (female-only)
  • 15 Feb 2018 Evoke Pharma files for patent protection in USA, relating to sex-based differences in metoclopramide (Gimoti™) exposure with the same dose of the medication
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top